Abstract:Polyglucosan storage disorders represent an emerging field within neurodegenerative and neuromuscular conditions. We combined molecular genetic analyses, quantitative mass spectrometry of laser micro‐dissected polyglucosan bodies, immunohistochemistry and western blot, and show that the absence of glycogenin‐1 (GYG1), a protein important for glycogen synthesis initiation, causes storage of polyglucosan that displays accumulation of several proteins, including those essential for glycogen synthesis, sequestosome 1/p62 and desmin. Aims Polyglucosan storage disorders represent an emerging field within neurodegenerative and neuromuscular conditions, including Lafora disease (EPM2A, EPM2B), adult polyglucosan body disease (APBD, GBE1), polyglucosan body myopathies associated with RBCK1 deficiency (PGBM1, RBCK1) or glycogenin‐1 deficiency (PGBM2, GYG1). While the storage material primarily comprises glycans, this study aimed to gain deeper insights into the protein components by proteomic profiling of the storage material in glycogenin‐1 deficiency. Methods We employed molecular genetic analyses, quantitative mass spectrometry of laser micro‐dissected polyglucosan bodies and muscle homogenate, immunohistochemistry and western blot analyses in muscle tissue from a 45‐year‐old patient with proximal muscle weakness from late teenage years due to polyglucosan storage myopathy. Results The muscle tissue exhibited a complete absence of glycogenin‐1 due to a novel homozygous deep intronic variant in GYG1 (c.7+992T>G), introducing a pseudo‐exon causing frameshift and a premature stop codon. Accumulated proteins in the polyglucosan bodies constituted components of glycogen metabolism, protein quality control pathways and desmin. Muscle fibres containing polyglucosan bodies frequently exhibited depletion of normal glycogen. Conclusions The absence of glycogenin‐1, a protein important for glycogen synthesis initiation, causes storage of polyglucosan that displays accumulation of several proteins, including those essential for glycogen synthesis, sequestosome 1/p62 and desmin, mirroring findings in RBCK1 deficiency. These results suggest shared pathogenic pathways across different diseases exhibiting polyglucosan storage. Such insights have implications for therapy in these rare yet devastating and presently untreatable disorders.

The Molecular Background of Glycogen Metabolism Disorders

Biochemical and clinical aspects of glycogen storage diseases

Glycogen metabolism and structure: A review

Glycogen metabolism and glycogen storage disorders

Glycogen storage diseases: New perspectives

Gene Therapy for Glycogen Storage Diseases

Molecular mechanisms of catalytic inhibition for active site mutations in glucose-6-phosphatase catalytic subunit 1 linked to glycogen storage disease

Neurological glycogen storage diseases and emerging therapeutics

Metabolic Profiling in Human Fibroblasts Enables Subtype Clustering in Glycogen Storage Disease

Molecular Genetics of Type 1 Glycogen Storage Disease

Glycogen Storage Diseases: A Brief Review and Update on Clinical Features, Genetic Abnormalities, Pathologic Features, and Treatment

Mechanism of glycogen synthase inactivation and interaction with glycogenin

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Laboratory diagnosis of the neuromuscular glycogen storage diseases

Molecular Characterization of Glycogen Storage Disease Type III

Recent developments in our understanding of glycogen structure

Pathobiology of the Hepatic Glycogen Storage Diseases

Glycogen storage diseases: Diagnosis, treatment and outcome

Glycogen Storage Disease: Clinical, Biochemical, and Molecular Heterogeneity

Myocardial glycogen dynamics: new perspectives on disease mechanisms.

Proteomic profiling of polyglucosan bodies associated with glycogenin‐1 deficiency in skeletal muscle